Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2023

Poster session 09

5P - Tertiary lymphoid structures (TLS) presence and stromal blood vessels heterogeneity differentially influence recurrence, lymphovascular, and perineural invasion in breast cancer molecular subtypes

Date

21 Oct 2023

Session

Poster session 09

Topics

Basic Science

Tumour Site

Breast Cancer

Presenters

Andrei Cosma

Citation

Annals of Oncology (2023) 34 (suppl_2): S187-S214. 10.1016/S0923-7534(23)01931-2

Authors

A.A. Cosma1, A.C. Barb1, S.M. Negru2, M.M. Pasca Fenesan2, A.M. Cimpean1

Author affiliations

  • 1 Department Of Microscopic Morphology/histology, UMFT - University of Medicine and Pharmacy Victor Babes, 300041 - Timisoara/RO
  • 2 Oncology Department, OncoHelp Oncology Center Timisoara, 300239 - Timisoara/RO

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Abstract 5P

Background

Tertiary Lymphoid Structures (TLS) mediate local antitumor immunity. Since cancer immunotherapy, TLS interests grown considerably. We examined TLS and tumor stromal blood vessels for BC molecular subtypes associated with recurrence, lymphovascu-lar (LIV), and perineural invasion (PnI).

Methods

CD34/SMA double immunostaining revealed TLS high endothelial venules and BC tumor stromal immature and mature blood vessels. Statistical study linked microscopic data to recurrence, LIV, and PnI.

Results

TLS- subgroups have higher LIV, PnI, and recurrence (p<0.001), except for Luminal A type. LIV and PnI rise in HER2+/TLS- subgroups (p<0.001). TNBC/TLS- had the highest recurrence and invasion risks. TNBC/TLS- subgroup recurrence is related to tumor grade and LIV/PnI (p<0.001), unlike other TLS- subgroups. PnI but not LVI are related with TNBC/TLS+ subgroup recurrence (p<0.001).

Conclusions

TLS affect BC molecular subtype recurrence, LVI, and PnI differently. Its antitumor immunity mediator seems closely associated to tumor aggressiveness and stromal blood vessels.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.